Hongbing Liu

16PUBLICATIONS
33CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 06, 2026
An exploratory ImmunoScore based on early on-treatment changes in NLR and LDH in small-cell lung cancer receiving first-line chemoimmunotherapy.

|Oct 22, 2024
First-line chemoimmunotherapy for patients with small-cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis.

Yu Li, Yuxin Jiang, Luyun Pan

|Oct 08, 2024
Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials.

Yunchang Meng, Qingfeng Zhang, Ranpu Wu

|Sep 12, 2024
Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials.

Yunchang Meng, Hedong Han, Suhua Zhu

|Aug 09, 2024
Immunohistochemistry identifies E-cadherin, N-cadherin and focal adhesion kinase (FAK) as predictors of stage I non-small cell lung carcinoma spread through the air spaces (STAS), and the combinations as prognostic factors.

Yunchang Meng, Yimin Wang, Leilei Liu

|Aug 02, 2024
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China.

Chunwei Xu, Zhanhong Chen, Yuanli Xia

Pageof 3

Frequent Collaborators

8 joint publications

Liyun Miao

7 joint publications

Yong Song

7 joint publications

Wenxian Wang

6 joint publications

Chunwei Xu